Julie Olsson

Learn More
INTRODUCTION In a subset of patients with asthma, standard-of-care treatment does not achieve disease control, highlighting the need for novel therapeutic approaches. Lebrikizumab is a humanised, monoclonal antibody that binds to and blocks interleukin-13 activity. METHODS LUTE and VERSE were replicate, randomised, double-blind, placebo-controlled(More)
  • 1